[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Cambodia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":423},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,68,99,132,167,189,217,254,276,370,396],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100496608","ending-tobacco-use-through-interactive-tailored-messaging-for-cambodian-people-living-with-hivaids-100496608",false,"NCT05746442","Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV\u002FAIDS","Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV\u002FAIDS (Project END-IT)","ProjectENDIT","Inclusion Criteria:\n\n* 1\\) being aged ≥18 years\n* 2\\) being HIV-positive\n* 3\\) self-reporting as a current combustible cigarette smoker (smoked ≥100 cigarettes in lifetime and currently smoke ≥1 cigarettes\u002Fday)\n* 4\\) willing to set a date for a quit attempt within 2 weeks of study enrollment\n* 5\\) being able to provide written informed consent to participate\n* 6\\) being able to read Khmer (score ≥4 points on the Rapid Estimate of Adult Literacy in Medicine-Short Form\n\nExclusion Criteria:\n\n* 1\\) history of a medical condition that precludes use of nicotine replacement therapy\n* 2\\) physician\u002Fclinician deemed ineligible to participate based on medical or psychiatric condition\n* 3\\) enrolled in another cessation program or use of other cessation medications.","ALL","18 Years",{"count":20,"type":21},800,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this research study is to test how well an automated text messaging smoking treatment program helps smokers with HIV quit smoking.",[27,28],"Smoking Cessation","HIV","RECRUITING","2026-08-11",{"date":32,"type":33},"2026-08-13","ACTUAL",{"date":35,"type":33},"2023-01-11",{"date":37,"type":21},"2027-09-30",{"name":39,"class":40},"H. Lee Moffitt Cancer Center and Research Institute","OTHER",3,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100619537","environment-pathogens-and-host-interactions-in-melioidosis-100619537","NCT07345910","Environment, Pathogens, and Host Interactions in Melioidosis","Decoding the Triad: the Interplay Between Environment, Pathogen, and Host in Melioidosis (DeEPH)","DeEPH","Inclusion criteria for melioidosis patients:\n\n* Age ≥20 years\n* Positive for Burkholderia pseudomallei from any clinical samples\n* Resident of the study area for at least two years, including the follow-up period\n* Willing to participate and give informed consent.\n\nInclusion criteria for healthy controls:\n\n* Age ≥20 years\n* Currently healthy as judged by study doctor\n* Resident of the study area for at least two years, including the follow-up period\n* Willing to participate and give informed consent.\n\nInclusion criteria for sandbox residents:\n\n* Age ≥20 years\n* Resident of the study area for at least two years, including the follow-up period\n* Willing to participate and give informed consent.\n\nExclusion criteria for melioidosis patients:\n\n* Current tuberculosis (TB) or TB treatment within the past six months\n* Documented HIV infection or use of immunosuppressive therapy in the past 12 months\n\nExclusion criteria for healthy controls:\n\n* History of melioidosis\n* Significant acute illness\n* Current fever or soft tissue infection\n\nExclusion criteria for sandbox residents\n\n-N\u002FA",true,"20 Years",{"count":53,"type":21},2400,"OBSERVATIONAL","This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.\n\nThe hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.\n\nFor each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.\n\nIn addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.\n\nThis study is funded by the Wellcome Trust. The grant reference number is 323077\u002FZ\u002F24\u002FZ",[57],"Melioidosis","NOT_YET_RECRUITING","2026-08-07",{"date":61,"type":33},"2026-08-10",{"date":63,"type":21},"2026-08-01",{"date":65,"type":21},"2034-12-01",{"name":67,"class":40},"University of Oxford",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":50,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100365132","febrile-disease-landscape-in-cambodia-via-metagenomic-pathogen-sequencing-100365132","NCT04034264","Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing","Characterization of Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated ICF.\n* Stated willingness to comply with all study procedures.\n* Male or female, aged at least 2 months\n* Meets one of the following case definitions:\n\n  * Febrile patient: has documented fever equal to or greater than 38 degrees celsius in previous 24 hours.\n  * Red flag patient: is an individual with disease relating to a red flag pathogen (see list, below), with confirmed standard laboratory testing (e.g., blood culture, polymerase chain reaction \\[PCR\\]) for the pathogen in question.\n  * Afebrile close contact: is an afebrile individual who lived in the same household or worked in the same enclosed workspace on a daily basis with a red flag patient at the time they got sick with a known pathogen.\n* Willing to allow biological samples to be stored for future research and for all de-identified metagenomic sequencing data to be stored in publicly accessible databases.\n\nEXCLUSION CRITERIA:\n\n* Any underlying, chronic, or current medical condition that, in the opinion of the investigator, would interfere with participation in the study (e.g., inability or great difficulty in drawing blood).\n* Any febrile individual who has had surgery in the prior month.\n* Any patient who enrolled and exited this study within 30 days of the initial study blood draw, or afebrile close contact who enrolled and exited within 14 days.","2 Months",{"count":77,"type":21},6500,"Background:\n\nVector-borne diseases are caused by the bite of an infected mosquito, fly, flea, tick, or other blood-feeder. These diseases cause almost 1 million deaths per year. And they are on the rise, particularly in Southeast Asia in particular. Researchers think that these diseases make up about 10 percent of fevers in Cambodia. But many of these illnesses are never diagnosed. Studying these diseases can help find new ways to identify and treat them.\n\nObjective:\n\nTo find pathogens in people who have a fever using metagenomic pathogen sequencing platforms.\n\nEligibility:\n\nPeople aged at least 2 months years with a fever of at least 38 degrees Celsius or those diagnosed with infection by a pathogen of concern who visit the referral hospital in Cambodia. Close contacts of people diagnosed with infection by a pathogen of concern may also be enrolled.\n\nDesign:\n\nParticipants will be screened with their medical history. Children will be weighed to make sure they are big enough to give blood samples.\n\nParticipants will share data about their sex, age, and where they live. They will answer more questions about their heath history. They will answer questions about and any places to which they have recently traveled. They will take a questionnaire. They will have a blood test. If they have respiratory symptoms, they will have a nasal swab.\n\nParticipants may be contacted within 1-2 weeks (early) and\u002For within 3 months (late) from their enrollment date to provide an optional follow-up blood samples and nasal swabs.",[80,81],"Vector-Borne Diseases","Emerging Pathogens",[83,80,84,85,86,87],"Next-Generation Sequencing","Southeast Asia","Agnostic Tools","Febrile Surveillance","Natural History","2026-07-29",{"date":90,"type":33},"2026-07-30",{"date":92,"type":33},"2019-07-23",{"date":94,"type":21},"2027-07-01",{"name":96,"class":97},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",6,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":98},"100416617","phase-4-southeast-asia-dose-optimization-of-tafenoquine-100416617","NCT04704999","Southeast Asia Dose Optimization of Tafenoquine","Optimizing the Dose of Tafenoquine for the Radical Cure of Plasmodium Vivax Malaria in Southeast Asia","SEADOT","Inclusion Criteria:\n\n* Patients with symptomatic P. vivax mono-infection as diagnosed by microscopy\n* Fever or history of fever in the previous 7 days\n* Quantitative G6PD activity ≥70% of the population median\n* Weight \\>10 kg and ≥2 years old\n* Ability to understand the study instructions and provide written informed consent.\n* Willing to be followed for 4 months\n\nExclusion Criteria:\n\n* Pregnancy\n* Lactation\n* Hb \\\u003C 8 g\u002FdL\n* Severe malaria\n* Blood transfusion in the last 4 months\n* History of allergic response to an 8-aminoquinoline or the nationally recommended schizonticide (e.g., chloroquine, artemether-lumefantrine)\n* Any previous history of a haemolytic event Presence of any condition which in the judgement of the investigator would place the patient at undue risk or interfere with the results of the study (e.g. chronic disease, medications that potentiate or inhibit CYP2D6 or CYP2C8 isoenzyme function)","2 Years",{"count":109,"type":21},820,[111],"PHASE4","Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the substantial advantage of single dosing as compared to a 14-day course of primaquine to achieve radical cure. The recommended tafenoquine dose is 300 mg, which was shown to be significantly worse in radical curative efficacy to a total primaquine dose of 3.5 mg\u002Fkg in Southeast Asia. The cure rate of tafenoquine 300 mg in Southeast Asian study sites was only 74%. The comparator 3.5 mg\u002Fkg total primaquine dose is the standard and most commonly used dose globally, but in Southeast Asia and the Western Pacific, higher doses of primaquine are needed for radical cure. This study aims to determine the optimal dose of tafenoquine in Southeast Asia.\n\nAddendum for Indonesia: The INSPECTOR trial results showed that tafenoquine 300mg was not efficacious for radical cure (79% probability for recurrence after treatment). The comparator arm, low-dose primaquine 3.5mg\u002Fkg divided equally over 14 days, showed a 48% probability of recurrence after treatment). The standard of care for radical cure in Indonesia is high-dose primaquine 7mg\u002Fkg divided in 7 daily doses).",[114],"Plasmodium Vivax Malaria",[116,117,118,119,120,121,122,123,124],"Plasmodium vivax","Relapse","8-aminoquinoline","Tafenoquine","Radical cure","Drug efficacy","Adults","Pediatrics","Primaquine","2026-07-27",{"date":88,"type":33},{"date":128,"type":33},"2024-07-22",{"date":130,"type":21},"2028-02-07",{"name":67,"class":40},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":144,"conditions":145,"keywords":151,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":41},"100522799","evaluation-of-a-multi-country-medical-oxygen-program-100522799","NCT06087315","Evaluation of a Multi-country Medical Oxygen Program","Realist Evaluation and Learning in a Multi-country Medical OXYgen Program (REAL-MOXY)","REAL-MOXY","Sub-study 1:\n\nResearch Question: What are the baseline pulse oximetry and oxygen practices for children admitted to participating health facilities, and what is the level of institutional readiness for oxygen service delivery? Which facilities, representative of high- and low-performing facilities and different levels of care and facility types, can be selected for additional investigation to understand current functioning of oxygen systems?\n\nSetting and Population: The broader MOXY program baseline cross-sectional assessments involve 9 countries. We have selected 6 MOXY countries for the mixed methods studies outlined in this protocol - Nigeria, Uganda, Liberia, Rwanda, Cambodia and Lao PDR - based on pre-existing research collaborations, and with the aim of representing broadly different geographical contexts.\n\nBaseline assessments are being conducted in all facilities participating in the MOXY program in each of the 6 study countries. From this data set, we will analyse primary and secondary outcomes for wards caring for children \\\u003C15 years (including neonatal wards where relevant).\n\nAnalysis\u002Foutcomes: Primary - proportion of admitted children (\\\u003C15 years, including neonates) screened with pulse oximetry. Secondary - proportion of admitted children with hypoxaemia (\\\u003C15 years, including neonates) treated with oxygen. For Real-Moxy the secondary outcome will inform identification of facilities for inclusion.\n\nSub-study 2:\n\nResearch question: Where and how are patients managed from arrival to admission and discharge (or transfer), and how does oxygen equipment move within and between clinical areas? How do process maps vary for different clinical scenarios representing different patient groups: i) pneumonia with and without hypoxaemia; ii) severe, acute illness syndrome with WHO emergency signs (e.g., shock, multi-trauma, seizures); iii) surgical condition and iv) neonatal illness (inborn and outborn)?\n\nSetting and Population: This will be conducted in 10 health facilities in each of the 6 countries (Nigeria, Uganda, Liberia, Rwanda, Lao PDR, Cambodia), selected to represent high and low functioning facility oxygen systems and include secondary and tertiary health facilities from government and non-governmental sectors (identified in sub-study 1). We will focus on admitted children (\\\u003C15 years, including neonates) with (i) pneumonia, (ii) other acute illness with WHO emergency signs, (iii) surgical conditions, and (iv) neonatal illness. We have chosen these conditions to represent diagnoses with a high prevalence of hypoxaemia, and to capture the nuances of how pulse oximetry and oxygen practices are adapted (or not adapted) to clinical scenarios (e.g., having a lower threshold to provide oxygen to a patient in shock; or targeting safe oxygen saturations in neonates).\n\nAnalysis\u002Foutcomes: Facility maps of patient and equipment flow.\n\nSub-study 3:\n\nResearch question: What is the sequence of emergency care for an unwell child in the first 4 hours, and how are decisions made - particularly relating to oxygen (when to start, stop, how much, what delivery modality, etc.)? What are the points of delays to appropriate care (including pulse oximetry and oxygen) and at what points in time and location could pulse oximetry and oxygen be used better for emergency care of children?\n\nSetting and Population: facilities are same as sub-study 2). Children (\\\u003C15 years, including neonates) presenting with each of 4 acute illness syndromes: (i) pneumonia, (ii) other acute illness with WHO emergency signs, (iii) surgical conditions, and (iv) neonatal illness.\n\nAnalysis\u002Foutcomes: Patient journey maps.\n\nSub-study 4:\n\nResearch question: How do healthcare workers use pulse oximetry and oxygen for admitted patients, and how does this change over time and vary between patient groups, facility type, and location? How do practices compare with treatment guidelines and where are the priority areas for improving oxygen care?\n\nPopulation and setting: Facilities are same as sub-studies 2\\&3.\n\nAnalysis\u002Foutcomes: Narrative descriptions of handover, ward rounds, and nursing rounds, with specific emphasis on how pulse oximetry is used, and decision making for oxygen therapy.\n\nSub-study 5: Indepth interviews and focus group discussions Research questions: 5a) How do patients\u002Fcaregivers perceive pulse oximetry and oxygen therapy within their broader care experience? 5b) How do healthcare workers, managers and technicians perceive oxygen therapy and the provision of oxygen-related care within the broader care provision experience?\n\nPopulation:\n\n* Patients and caregivers enrolled in sub-study 3 (patient journey mapping).\n* Healthcare workers (bedside), managers (including clinical and non-clinical managers) and technicians in each health facility. We will select staff with direct responsibility for wards caring for children \\\u003C15 years.\n\nAnalysis\u002Foutcomes: Reflexive thematic analysis of interviews and focus group discussions.","0 Years","15 Years",{"count":143,"type":21},1200,"REAL-MOXY is a set of 5 mixed methods studies designed to understand how oxygen and pulse oximetry are used (or not used) at a facility level, to identify opportunities and barriers for strengthening oxygen systems for beneficiaries, users and managers.",[146,147,148,149,150],"Hypoxemia","Neonatal Disease","Pneumonia","Sepsis","Morality",[152,153,154,155,156,157],"Oxygen systems","Pulse oximetry","Low middle income countries","Global health","Mixed-methods evaluation","Realist evaluation","2026-07-06",{"date":160,"type":33},"2026-07-08",{"date":162,"type":33},"2023-11-27",{"date":164,"type":21},"2027-12",{"name":166,"class":40},"Murdoch Childrens Research Institute",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100568409","characterization-of-human-immune-signatures-to-zoonotic-virus-exposure-in-cambodia-100568409","NCT06680843","Characterization of Human Immune Signatures to Zoonotic Virus Exposure in Cambodia","Camzoo","Inclusion Criteria:\n\n1. Capacity to provide informed consent.\n2. Adult aged 18-65 years.\n3. Have interaction with suspected infected animals within the last 2 years, including (but not limited to) the following risk factors:\n\n   1. Hunting, slaughtering, or consuming suspected infected animals;\n   2. Fruit collection, date palm sap harvesting, or tree pruning within agricultural plantations containing bat roosts;\n   3. Bat guano farming;\n   4. Ancillary work in live animal markets or wild animal habitats identified as likely containing infected animals (e.g., provision of cleaning, transportation, or tourism services);\n   5. Living within 5 km of identified animal markets or wild animal habitats identified as likely containing infected animals.\n4. Willing to allow biological samples and data to be stored for future research.\n\nExclusion Criteria:\n\n1. Pregnancy (based on self-reporting).\n2. Any underlying, chronic, or current medical condition that, in the opinion of the investigator, would interfere with participation in the study (e.g., inability or great difficulty in drawing blood, known anemia).\n3. Self-reported symptoms suggestive of acute infection (acute myalgias, arthralgias, headache, retro-orbital pain, dyspnea, rash) within 7 days prior to enrollment.\n4. Signs suggestive of acute infection (fever, defined as internal temperature \\>38°C; hypoxemia, defined as peripheral oxygen saturation of \\\u003C90%; hypotension, defined as systolic blood pressure \\\u003C90 mm Hg or diastolic blood pressure \\\u003C50 mm Hg) present at screening.\n5. Self-reported diagnosis of immune deficiency, including HIV infection, chronic corticosteroid use (≥10 mg prednisone dose or its equivalent for a continuous period of ≥30 days within the last 1 year), ongoing or prior (within the last 10 years) receipt of chemotherapy or immunotherapy, or current hematological malignancy.\n6. Receipt of blood products, including immunoglobulin products, within 120 days of study enrollment.","65 Years",{"count":176,"type":21},400,"This is a biospecimen procurement protocol to characterize the immune response to zoonotic virus exposure in healthy adult humans aged 18 to 65 years with high-risk exposure to animals or their excreta (e.g., guano farming and wet markets), or living within 5 km of animal habitats (e.g., bat caves and bat roosts) in Cambodia.",[179],"Immunity, Humoral","2026-05-05",{"date":182,"type":33},"2026-05-06",{"date":184,"type":33},"2024-11-01",{"date":186,"type":21},"2028-05-01",{"name":96,"class":97},5,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100588539","applied-implementation-research-for-clean-cooking-in-cambodia-100588539","NCT06942715","Applied Implementation Research for Clean Cooking in Cambodia","Applied Implementation Research for Clean Cooking in Cambodia: Equity, Exposure, Costs, and Benefits of Induction Stove Interventions","AIR-C3","Inclusion Criteria:\n\n\\- A household must:\n\n* Provide consent to participate in our study, with at least one adult household member who identifies as the primary cook consenting to serve as the study participant\n* Resides in village selected for implementation\n* Household has electricity access\n* Household does not already use electricity-based induction cooking technology\n\nExclusion Criteria:\n\n-Plans to move permanently outside the study area in the next 12 months",{"count":198,"type":21},6150,[24],"The goal of this study is to learn how to help families in Cambodia switch to using electric induction stoves instead of traditional stoves that burn wood or charcoal. The study will also look at whether this switch is safe, affordable, and sustainable over time.\n\nThe main questions researchers want to answer are:\n\n* What strategies work best to encourage families to use induction stoves regularly and stop using traditional cooking methods?\n* Does switching to induction cooking reduce household air pollution for primary cooks?\n* What are the costs and benefits of these strategies?\n\nTo answer these questions, researchers will compare different strategies across 65 peri-urban villages in Cambodia. They will use data loggers to track when families use induction stoves or traditional stoves, and measure air pollution levels in the home before and after families receive induction stoves.\n\nParticipants will:\n\n* Receive an electric induction stove and support based on their group's strategy\n* Have their stove use tracked through special devices\n* Take part in air pollution measurements in their homes\n* Share information about their cooking habits and experiences",[202,203],"Exposure to Environmental Pollution","Exposure to Household Air Pollution",[205,206],"Cooking methods","Induction stoves","2026-03-30",{"date":209,"type":33},"2026-04-03",{"date":211,"type":33},"2025-10-13",{"date":213,"type":21},"2029-05",{"name":215,"class":40},"Emory University",1,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":50,"sex":225,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":228,"conditions":229,"keywords":237,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":216},"100623758","assessing-health-system-readiness-for-scaling-antenatal-mms-in-cambodia-100623758","NCT07400796","Assessing Health System Readiness for Scaling Antenatal MMS in Cambodia","Assessing Health System Readiness for Scaling Antenatal MMS in Cambodia: A Mixed-Methods Assessment","TIPS-Cambodia","For the cohort of pregnant individuals consuming MMS:\n\nInclusion Criteria:\n\n* Current pregnant\n* At least 18 years of age\n* Have attended at least one ANC visit at a health center or hospital in Takeo during the study period\n* Can provide a functioning phone number for follow-up contact\n* Willingness to participate and provide consent\n\nExclusion Criteria:\n\n* Individuals with diagnosed anemia who require iron and folic acid (IFA) supplementation instead of MMS\n* Individuals unable to communicate via telephone,;(3) individuals who withdraw consent at any point","FEMALE",{"count":227,"type":21},710,"Malnutrition among pregnant women in low- and middle-income countries (LMICs) can cause micronutrient deficiencies that result in adverse maternal and neonatal health outcomes. The World Health Organization has recently recommended antenatal multiple micronutrient supplementation (MMS) that includes iron and folic acid (IFA) to improve maternal and neonatal health outcomes. MMS likely provides additional antenatal benefits over IFA supplementation alone. The Cambodian government, in partnership with Helen Keller International, is piloting MMS implementation in Takeo Province, which will inform nationwide scale-up of MMS.\n\nStudy Purpose: The Takeo implementation must be evaluated to understand context-specific implementation of MMS and health system readiness for scale-up. This study assesses system readiness through four domains from the Intervention Scalability Assessment Tool (ISAT): (1) fidelity and adaptation, (2) reach and acceptability, (3) delivery setting and workforce capacity, and (4) implementation infrastructure.\n\nPopulation: The pilot involves transitioning to MMS from IFA across all 86 health centers, all 6 referral hospitals, and the provincial hospital in Takeo province. This study includes pregnant women receiving antenatal care, antenatal healthcare providers and facilities, and hospital managers in Takeo. The study also includes national governing bodies for MMS delivery.\n\nMethods: This mixed-methods study uses ISAT as a framework for developing data collection methods. Sampling strategies emphasize urban and rural representation across all operational districts in Takeo and diverse stakeholder perspectives at multiple levels of the health system. Data collection includes:\n\n* 12 focus group discussions (FGDs) with health center providers to assess provider adherence to MMS delivery guidelines, perspectives on the transition to MMS, and additional resources needed for MMS delivery\n* Workload assessment surveys at FGDs to quantify any burden on providers and resource gaps to deliver MMS\n* MMS stockout monitoring at 18 health centers and 7 hospitals to assess supply chain reliability\n* 15 key informant interviews with hospital managers to assess perspectives on the integration of MMS into antenatal services and facility readiness for MMS delivery\n* Phone surveys with 630 pregnant women to assess acceptability and adherence to MMS at 90- and 180-days after MMS distribution\n* One FGD with national-level stakeholders to assess national-level readiness, economic planning, and resource planning for sustainable MMS implementation and scale-up\n* Rapid economic evaluation to estimate the cost of nationwide scale-up Potential Impact: This study will generate insights into real-world implementation of MMS in Cambodia. It will identify context-specific adaptations, implementation gaps, and resource planning frameworks needed for nationwide scale-up of MMS. Successful scale-up is anticipated to improve maternal and neonatal health in Cambodia. Findings can also be used to guide other LMICs seeking to transition to and sustainably implement MMS.",[230,231,232,233,234,235,236],"Anemia","Pregnancy","Micronutrients","Supplement","Health Systems","Supply Chain Vulnerabilities","Adherence",[238,239,240,241,242,243,244],"anemia","nutrition","micronutrient","supplement","dietary supplement","Cambodia","policy","2026-02-12",{"date":247,"type":33},"2026-02-17",{"date":249,"type":33},"2025-12-01",{"date":251,"type":21},"2026-06-30",{"name":253,"class":40},"University of British Columbia",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":275,"locationsCount":98},"100529110","health-systems-and-policy-contexts-of-medical-oxygen-100529110","NCT06169514","Health Systems and Policy Contexts of Medical Oxygen","Understanding the Health Systems and Policy Contexts of Medical Oxygen in Africa and Asia (MOXY-HSP)","MOXY-HSP","Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society.",{"count":216,"type":21},"This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies. This study aims to understand how national oxygen strategies achieve impact at national, and subnational level, across country contexts, at what cost.\n\nThe the investigators seek to:\n\n1. Involve policymakers, implementers (including private sector), and medical oxygen users in identifying challenges and understanding potential solutions to medical oxygen access;\n2. Generate new data on how medical oxygen systems work and can be improved from multiple perspectives;\n3. Draw lessons on medical oxygen that can directly inform national and global practice and policy.\n\nThis study will be conducted in 6 of the 9 countries participating in the Clinton Health Access Initiative (CHAI) led Medical Oxygen Implementation (MOXY) program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).\n\nKey informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society. This study will be completed over 4 years, with timelines varying between country study sites.",[146,150,148],[266,267,152,268,153],"Health system","Oxygen","Oxygen access","2026-02-04",{"date":271,"type":33},"2026-02-06",{"date":273,"type":33},"2024-07-31",{"date":164,"type":21},{"name":166,"class":40},{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":50,"sex":17,"minAge":107,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":286,"conditions":287,"keywords":345,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":216},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","75 Years",{"count":285,"type":21},10000,"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[288,289,290,291,292,293,294,295,296,297,298,299,300,57,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,243],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","2026-01-14",{"date":364,"type":33},"2026-01-22",{"date":366,"type":33},"2025-12-18",{"date":37,"type":21},{"name":369,"class":40},"Institut Pasteur du Cambodge",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":50,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":378,"targetDuration":380,"studyType":54,"phases":4,"briefSummary":381,"conditions":382,"keywords":383,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":41},"100596034","immune-responses-to-dengue-and-sepsis-100596034","NCT07040202","Immune Responses to Dengue and Sepsis","Evaluating Immune Responses to Dengue and Sepsis in Hospitalized Patients in Cambodia","DEN-SEP","Inclusion Criteria:\n\n* Patients with dengue-like illness:\n\nPatients presenting with dengue-like symptoms for a duration of maximum 72h before inclusion. Dengue-like symptoms include: presentation with oral temperature \\>38°C AND at least two of the following symptoms suggestive of dengue-like illness: headache, retro-orbital pain, myalgia, joint pain, rash, any bleeding symptoms, nausea or vomiting, lethargy or restlessness , abdominal pain, liver enlargement\n\n* Sepsis patients:\n\nPatients admitted for less than 48 hours with a primary diagnosis of sepsis as per treating team AND have blood cultures ordered AND on empiric antibiotics due to concern for bacterial infection.\n\n* Healthy controls:\n\nParticipants with no chronic illness, no regular medications, no febrile illness in 28 days, no diagnosis of or treatment for dengue or bacterial infection in the past 6 months.\n\nExclusion Criteria:\n\n* For biobanking purposes, children less than 2 years of age, and individuals who are pregnant, pregnant within the last 90 days, and\u002For breastfeeding are excluded due to restrictions on the blood volumes and the repeated sampling times.\n* Individuals that do not provide informed consent will not be included for the study.\n* Severe\u002Fchronic\u002Frecurrent pathological conditions: clinically significant autoimmune disease or immunodeficiency (including history of organ transplant), haematologic disorders, cardiac diseases, diabetes, cancer, HIV, chronic hepatic or renal insufficiency.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within the 6 months prior to the inclusion. For corticosteroids, this will mean a dose equivalent to 20 mg\u002Fday of prednisone or equivalent for \\> 2 weeks (inhaled and topical steroids allowed)\n* Chronic administration of NSAIDs, including aspirin: prolonged intake (\\>2 weeks) within 6 months before study or any intake within the 7 days preceding sampling \\[exception for low dose aspirin: maximum 250mg\u002Fdaily\\]\n* Any underlying, chronic, or current condition that, in the opinion of the investigator, may interfere with their participation in the study.\n* Expected death in the next 48-hours",{"count":379,"type":21},240,"21 Days","The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, sepsis, or healthy people. The investigators will perform multiple analyses on the blood samples and compare results between dengue patients and those with sepsis and healthy people.",[288,149],[384,385,386,387],"dengue","sepsis","observational","infection","2025-06-24",{"date":390,"type":33},"2025-06-27",{"date":392,"type":33},"2025-06-02",{"date":394,"type":21},"2026-12",{"name":369,"class":40},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":216},"100496510","pilot-implementation-of-hiv-self-testing-delivery-in-private-pharmacies-combined-to-a-respondent-driven-sampling-method-to-improve-hiv-testing-for-msm-and-tgw-in-phnom-penh---anrs-0100s-100496510","NCT05745168","Pilot Implementation of HIV Self-testing Delivery in Private Pharmacies Combined to a Respondent Driven Sampling Method to Improve HIV Testing for MSM and TGW in Phnom Penh - ANRS 0100s","Inclusion Criteria:\n\n* To be aged from 18 years old (legal age in Cambodia)\n* For MSM, to have at least one oral or anal intercourse with another man in the past 12 months\n* For TGW, to be biologically a male at birth and self-identified as a woman or third gender and have at least one oral, anal or vaginal intercourse with another man in the past 12 months\n\nExclusion Criteria\n\n* Known HIV positive status",{"count":403,"type":21},1500,"The study aims to evaluate the feasibility of HIV self-testing (HIVST) delivery by a private pharmacy network among men who have sex with men (MSM) and transgender women (TGW) recruited through a classic and digital Respondent Driven Sampling method to improve HIV testing in Phnom Penh, Cambodia.\n\nAn interventional pilot study using a mixed qualitative and quantitative approach will be carried out in order to evaluate the feasibility, acceptability and appropriateness of the strategy and to identify barriers and facilitators.",[406],"HIV Infections",[408,409,410,411,412],"Self-testing","Private pharmacy","RDS","MSM","Transgender women","2024-01-29",{"date":415,"type":33},"2024-01-30",{"date":417,"type":21},"2024-06",{"date":419,"type":21},"2026-10",{"name":421,"class":422},"ANRS, Emerging Infectious Diseases","OTHER_GOV",""]